Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700008 | 0.85 | CHRNA7 (0.54) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4701182 | 0.84 | CHRNA7 (0.42) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4701749 | 0.83 | CHRNA7 (0.45) | CHRNA7HTR3A | |
| SCHEMBL4700021 | 0.82 | CHRNA7 (0.45) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4702367 | 0.81 | CHRNA7 (0.45) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4700378 | 0.81 | DRD2 (0.45) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4703053 | 0.81 | DYRK1A (0.43) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4700170 | 0.80 | CHRNA7 (0.46) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4702396 | 0.80 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4700154 | 0.80 | ESRRG (0.43) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | CHRNA7 6/4885HTR3A 162/4885HTR3E 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.